Lorenzo Martellone

Dr. Lorenzo Martellone

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Marine Environmental Research
Verified
Journal Article
Closed access
CBChiara Bruno
Chiara Bruno
MBMonica Francesca Blasi
Monica Francesca Blasi
DMDaniela Mattei
Daniela Mattei
LMLorenzo Martellone
Lorenzo Martellone
EBEleonora Brancaleone
Eleonora Brancaleone
Gabriele FaveroGabriele Favero
Gabriele Favero

4 March 2026 in Applied Health Economics and Health Policy
Verified
Journal Article
Open access
LMLorenzo Martellone
Lorenzo Martellone
CSCamilla Servidio
Camilla Servidio
MVMarcello Vaccaro
Marcello Vaccaro
KMKatiuscja Malandrini
Katiuscja Malandrini
ACAdriana Coluccia
Adriana Coluccia
GPGiacomo Polito
Giacomo Polito
The Italian assessment system for innovative medicines represents a distinctive European regulatory approach. Integrated with the Italian Medicines Agency (AIFA), since 2017 it has provided a formal evaluation based on three predefined criteria, Therapeutic Need (TN), Added Therapeutic Value (ATV) and Quality of Evidence (QoE), granting access to dedicated funds and simplified procedures. This study investigated the evolution of the Italian system from 2017 to the 2025 reform, focusing on outcomes, decision criteria, timelines, and financial implications. Publicly available AIFA data on 266 assessments were analysed and stratified by outcome, therapeutic area, orphan status and Advanced Therapy Medicinal Product (ATMP) designation. Logistic regression models were used to assess the internal consistency of appraisal criteria and to explore whether regulatory attributes modified their association with innovativeness outcomes. Time to recognition (TIR) and Decision-to-Implementation Interval (DII) were calculated for "Full Innovative" medicines. Annual spending was compared to fund availability to assess the financial impact of innovative medicines. Among the 266 evaluations, approximately 29% were classified as "Full Innovative", 29% "Conditionally Innovative" and 42% "Not Innovative". Added Therapeutic Value and QoE showed the strongest associations with positive designations, while orphan and ATMP status showed no independent association. Access timelines were comparable across therapeutic areas, with slightly longer delays for ATMPs. Spending exceeded fund limits several times but fell below budget after fund unification in 2022. The Italian system has been applied consistently over time, with appraisal outcomes largely reflecting the formal decision criteria rather than regulatory status. The 2025 reform may represent a turning point, potentially changing designation patterns and their determinants. Ongoing monitoring is needed to ensure access does not compromise evidence standards or sustainability, offering lessons that may be relevant to other health systems considering similar mechanisms.

11 June 2026 in Value in Health Regional Issues
Verified
Journal Article
Open access
LMLorenzo Martellone
Lorenzo Martellone
CSCamilla Servidio
Camilla Servidio
CLCristiana Leanza
Cristiana Leanza
DTDario Tomolillo
Dario Tomolillo
ALAngela Lorusso
Angela Lorusso
GPGiacomo Polito
Giacomo Polito
Traditional budget impact analysis models, usually based on predefined populations, often fail to capture the complexity of hospital antibiotic use, which is dynamic and often empirical. To address this gap, we developed and applied an adaptable budget impact analysis model based on real-world consumption data of high-cost reserve antibiotics (HCR-ABX), with the objective of projecting their short-term budget impact in a large university hospital over a 3-year horizon. HCR-ABX with a purchase cost >€100/defined daily doses (DDD) were selected. The model used retrospective hospital pharmacy data (2021-2024) and incorporated national guidelines on multidrug-resistant infections, regulatory/reimbursement updates, and local resistance trends. These inputs were used to define drug-specific annual variation rates applied in the projection scenarios. Future costs were estimated by combining projected consumption (DDD/100 hospitalization days) with the hospital purchase cost per DDD. Three forecast scenarios (base case, lower impact, higher impact) plus a Klebsiella pneumoniae stress-test scenario were modeled. Despite approximately stable overall HCR-ABX consumption, a shift toward higher-cost agents was observed. The base-case scenario projected a cumulative expenditure of approximately €10 586 248 over 3 years, with increases driven by meropenem/Vaborbactam and cefiderocol. The lower-impact and higher-impact scenarios estimated €10 062 688 and €11 050 385 €, respectively. The Klebsiella pneumoniae stress-test scenario indicated a total cost of € 11 321 117 (+6.95% vs base-case scenario), emphasizing the potential financial impact of epidemiological shifts. The proposed model provides a pragmatic, adaptable framework to assess the hospital budget impact of HCR-ABX and supports antimicrobial stewardship. The approach is replicable and can be refined through future validation against observed data.

1 June 2026 in Targets
Verified
Journal Article
Open access
PDF file
RGRiccardo Gennari
Riccardo Gennari
NCNicole CAPRETTI
Nicole CAPRETTI
DDDanial Daroui
Danial Daroui
STSergio Terracina
Sergio Terracina
LMLorenzo Martellone
Lorenzo Martellone
GGGiuseppe Greco
Giuseppe Greco
Gambling disorder (GD) constitutes a worldwide social and economic burden and is associated with impaired functioning and reduced quality of life. GD shares important mechanistic substrates with obsessive–compulsive disorder (OCD), including dysfunction of cortico-striato-thalamo-cortical circuitry and dysregulation of serotonergic pathways involved in impulsivity, compulsivity, and impaired inhibitory control. On this basis, selective serotonin reuptake inhibitors (SSRIs), widely used in several psychiatric disorders, have been investigated as potential pharmacological treatments for GD. Evidence concerning fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram is heterogeneous and overall limited. Some early single-blind, randomized, and open-label studies have reported reductions in gambling urges, severity, and compulsive symptoms. However, larger and more rigorous placebo-controlled trials have frequently failed to demonstrate consistent superiority over placebo. Interpretation of these findings is further limited by small sample sizes, short observation periods, high dropout rates, heterogeneous outcome measures, and substantial placebo response. While SSRIs remain biologically plausible candidates for modulating the compulsive and impulsive dimensions of GD, current evidence does not support their routine use as first-line pharmacological treatment. Their role appears most justified in the presence of psychiatric comorbidity or within individualized, phenotype-oriented treatment strategies.

15 July 2026 in Global and Regional Health Technology Assessment
Verified
Journal Article
Open access
PDF file
LMLorenzo Martellone
Lorenzo Martellone
AZAndrea Zovi
Andrea Zovi
GPGiacomo Polito
Giacomo Polito
The AIFA (Agenzia Italiana del Farmaco) monitoring registries represent one of the most distinctive regulatory tools within the Italian pharmaceutical governance framework. Initially introduced to support the appropriate use of reimbursed medicines and pharmaceutical expenditure control, they have progressively evolved into an infrastructure linking access to medicines, reimbursement governance, managed entry agreements (MEAs), and real-world data collection. This article examines the evolution and the policy relevance of AIFA monitoring registries within the Italian Health Technology Assessment framework. Firstly, it outlines the legislative and regulatory milestones shaping the system, from the establishment of AIFA in 2003 to the publication of the 2024 guideline, which formally defined the criteria for registry activation. Secondly, it describes the registry types, the criteria guiding their establishment, and the role of MEAs within the monitoring process. Thirdly, it provides an updated overview of the current registry landscape based on AIFA lists, identifying 340 closed registries (March 2026) and 366 active registries (April 2026), with “registri propriamente detti” (comprehensive registries) representing the predominant tool. Among those registries, MEAs were applied in nearly half of cases, with payment by result being the commonest scheme. The article also reviews the use of registry-derived data in peer-reviewed studies across hematology, oncology, cardiovascular diseases, and infectious diseases. Finally, it discusses key challenges, including duplication of information, limited interoperability with healthcare databases, administrative burden and residual discretion in registry activation despite recent transparency reforms. Overall, AIFA monitoring registries emerge as a strategic interface between pharmaceutical regulation, reimbursement governance, and evidence generation.